title: The discriminating properties of an optoelectronic movement analysis method in patients with parkinsonism.
abstract: Several partly overlapping diseases have Parkinsonism as a symptom and tools that may differentiate between these disorders would be helpful. The authors evaluated the discriminating properties of the objective automated posturo-locomotor-manual (PLM) L-DOPA test in regard to health, and the movement disorders Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). A PLM test-retest procedure was performed in healthy controls (n = 37) and results were compared with PLM L-DOPA tests performed by 132 patients with Parkinsonism in intermediate to advanced stages (56 PD, 53 MSA, 23 PSP). The movement time (MT) for the standardized movement and its different components was measured. The discriminating abilities of individual, or combinations of, test variables were determined by forward stepwise multiple logistic regression and evaluated with receiver-operating characteristic (ROC) analysis. Each PLM variable separated healthy persons from patients with Parkinsonism before administration of L-DOPA (area under the curve (AUC) = 0.94-0.99, p < .001 for any separate variable). A combination of (MToff - MTon)/MToff and MTon had the highest ability to separate patients with PD from patients with atypical Parkinsonism (area under the curve = 0.91, p < .001). The PLM test discriminates between healthy controls and patients with Parkinsonism, and between patients with Parkinson's disease and patients with atypical Parkinsonism.
authors: Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation, University of Gothenburg, Sweden. theresa.zackrisson@neuro.gu.se
authors: Theresa
authors: T
authors: Zackrisson
authors: Filip
authors: F
authors: Bergquist
authors: Mats
authors: M
authors: Eklund
authors: Björn
authors: B
authors: Holmberg
authors: Thorleif
authors: T
authors: Thorlin
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D016014:Linear Models; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009068:Movement / Q000502:physiology*; D019578:Multiple System Atrophy / Q000175:diagnosis / Q000503:physiopathology; D020734:Parkinsonian Disorders / Q000175:diagnosis / Q000503:physiopathology*; D011187:Posture / Q000502:physiology; D012372:ROC Curve; D015203:Reproducibility of Results; D013494:Supranuclear Palsy, Progressive / Q000175:diagnosis / Q000503:physiopathology
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa